ASCO15: Hanmi Pharmaceutical To Present Its New Targeted Lung Cancer Drug 'HM61713' At 2015 ASCO Annual Meeting
SEOUL, South Korea--(BUSINESS WIRE)--Hanmi Pharmaceutical co., Ltd. (KSE:128940) will present the results of the phase I/II domestic clinical trial of HM61713 in patients with EGFR mutation positive non-small cell lung cancer at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2015, in Chicago, USA.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.